CDR2 anticorps (N-Term)
Aperçu rapide pour CDR2 anticorps (N-Term) (ABIN629700)
Antigène
Voir toutes CDR2 AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- N-Term
-
Specificité
- CDR2 antibody was raised against the N terminal of CDR2
-
Purification
- Purified
-
Immunogène
- CDR2 antibody was raised using the N terminal of CDR2 corresponding to a region with amino acids MLAENLVEEFEMKEDEPWYDHQDLQQDLQLAAELGKTLLDRNTELEDSVQ
-
-
-
-
Indications d'application
-
WB: 5 µg/mL, IHC: 4-8 µg/mL
Optimal conditions should be determined by the investigator. -
Commentaires
-
CDR2 Blocking Peptide, (ABIN5612802), is also available for use as a blocking control in assays to test for specificity of this CDR2 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of CDR2 antibody in PBS
-
Concentration
- Lot specific
-
Buffer
- PBS
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- CDR2 (Cerebellar Degeneration-Related Protein 2, 62kDa (CDR2))
-
Autre désignation
- CDR2
-
Sujet
- Cdr2 normally sequesters c-Myc in the neuronal cytoplasm, thereby down-regulating c-Myc activity, and suggest a mechanism whereby inhibition of cdr2 function by autoantibodies in PCD may contribute to Purkinje neuronal.
-
Poids moléculaire
- 52 kDa (MW of target protein)
Antigène
-